Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY-NC 4.0Kidney & Blood Pressure Research

Endothelial-to-Mesenchymal Transition in Chronic Kidney Disease: Mechanisms and Therapeutic Targets

5 affiliations
  1. 1Department of Anesthesiology and Perioperative Medicine, University of Missouri, Columbia, MO, USA
  2. 2Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
  3. 3Department of Physiology, Kerala Veterinary and Animal Sciences University, Pookode, India
  4. 4Department of Medical Pharmacology and Physiology, University of Missouri, Columbia, MO, USA
  5. 5NextGen Precision Health, University of Missouri, Columbia, MO, USA

Abstract

Background: Renal fibrosis is the final common pathological outcome of chronic kidney disease (CKD) and a major driver of progression to end-stage kidney disease. Endothelial-to-mesenchymal transition (EndMT) is a phenotypic process in which endothelial cells lose their endothelial identity and acquire mesenchymal or myofibroblast-like characteristics, thereby contributing to extracellular matrix accumulation, capillary rarefaction, microvascular dysfunction, and fibrotic remodeling.

Summary: Transforming growth factor-β (TGF-β) is a central inducer of EndMT through canonical Smad-dependent and noncanonical Smad-independent signaling pathways. Additional pathways, including Wnt/β-catenin, Notch, Hedgehog, inflammatory cytokine signaling, autophagy dysregulation, oxidative stress, and metabolic reprogramming, further regulate EndMT in the diseased kidney. This review summarizes the cellular and molecular mechanisms underlying EndMT in CKD, highlights interactions among major regulatory pathways, and discusses emerging pharmacological strategies to inhibit EndMT, preserve renal microvascular integrity, and attenuate fibrogenesis.

Key Messages: Growing evidence supports an important role for EndMT in renal fibrosis and CKD progression. However, the quantitative contribution of EndMT to human kidney fibrosis, the biological significance of partial or hybrid EndMT states, and the most effective approaches for therapeutically targeting this process remain incompletely defined. Advances in lineage-tracing, single-cell and spatial transcriptomics, biomarker development, and pathway-selective therapies will be essential for translating EndMT-directed interventions into clinical practice.

Related

  1. Epithelial-mesenchymal transition plasticity in breast cancer: regulatory mechanisms and therapeutic implications
    Chunlei Wang, Jie Cao, Bo Qin
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMCPMC
  2. Identifying potential targets in endothelial to mesenchymal transition-mediated atherosclerosis using bioinformatics and machine learning
    Zhengjun Hou, Sihan Chen, Yuliang Cui +3
    PeerJPeer-reviewedCC BY-NC 4.0Full textBioinformatics & computational biologyCardiovascular medicineCrossrefPMC
  3. Macrophage-derived IL-1β drives endothelial-mesenchymal transition in diabetes mellitus erectile dysfunction
    Yijun Zhang, Siyu Liu, Wenhao Wang +9
    Cell & BiosciencePeer-reviewedCC BY-NC-ND 4.0Full textPsychiatry & mental healthPMC
  4. HDAC6 is a novel regulator of endothelial-to-mesenchymal transition in venous thrombosis
    M. Pilard, V. Gourdou-Latyszenok, L. Gourhant +11
    bioRxivPreprintCC BY-NC-NDFull textPhysiologybioRxiv
  5. From epithelial-mesenchymal transition to liquid biopsy: mechanisms of gastric cancer metastatic dissemination and circulating biomarker-guided anti-recurrence strategies
    Tianlu Chu, Peipei Yang, Peng Shu
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyFrontiersCrossref
BibTeX
@article{khan2026endothelialtomesenchymal,
  title = {{Endothelial-to-Mesenchymal Transition in Chronic Kidney Disease: Mechanisms and Therapeutic Targets}},
  author = {Abdul H. Khan and Pratheesh D. Mankuzhy and Linto Thomas and Adebowale Adebiyi},
  journal = {Kidney \& Blood Pressure Research},
  year = {2026},
  month = jul,
  doi = {10.1159/kbr/adjag001},
  url = {https://doi.org/10.1159/kbr/adjag001},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Endothelial-to-Mesenchymal Transition in Chronic Kidney Disease: Mechanisms and Therapeutic Targets
AU  - Abdul H. Khan
AU  - Pratheesh D. Mankuzhy
AU  - Linto Thomas
AU  - Adebowale Adebiyi
PY  - 2026
DA  - 2026/07/28
JO  - Kidney & Blood Pressure Research
DO  - 10.1159/kbr/adjag001
UR  - https://doi.org/10.1159/kbr/adjag001
AB  - Background: Renal fibrosis is the final common pathological outcome of chronic kidney disease (CKD) and a major driver of progression to end-stage kidney disease. Endothelial-to-mesenchymal transition (EndMT) is a phenotypic process in which endothelial cells lose their endothelial identity and acquire mesenchymal or myofibroblast-like characteristics, thereby contributing to extracellular matrix accumulation, capillary rarefaction, microvascular dysfunction, and fibrotic remodeling.  Summary: Transforming growth factor-β (TGF-β) is a central inducer of EndMT through canonical Smad-dependent and noncanonical Smad-independent signaling pathways. Additional pathways, including Wnt/β-catenin, Notch, Hedgehog, inflammatory cytokine signaling, autophagy dysregulation, oxidative stress, and metabolic reprogramming, further regulate EndMT in the diseased kidney. This review summarizes the cellular and molecular mechanisms underlying EndMT in CKD, highlights interactions among major regulatory pathways, and discusses emerging pharmacological strategies to inhibit EndMT, preserve renal microvascular integrity, and attenuate fibrogenesis.  Key Messages: Growing evidence supports an important role for EndMT in renal fibrosis and CKD progression. However, the quantitative contribution of EndMT to human kidney fibrosis, the biological significance of partial or hybrid EndMT states, and the most effective approaches for therapeutically targeting this process remain incompletely defined. Advances in lineage-tracing, single-cell and spatial transcriptomics, biomarker development, and pathway-selective therapies will be essential for translating EndMT-directed interventions into clinical practice.
SN  - 1420-4096
SN  - 1423-0143
ER  -